ORLANDO, FL, USA (UroToday.com) - The objective of this study was to assess if the addition of dasatinib to a docetaxel/prednisone regimen, the current standard of care chemotherapy, would provide clinical benefit as first-line therapy in patients with mCRPC....Click here to enlarge and view the poster
Click here to read session highlights by a UroToday.com medical reporter
Presented by John Araujo,1 Géralyn C. Trudel,2 Fred Saad,3 Andrew Armstrong,4 Evan Y. Yu,5 Joaquim Bellmunt,6 George Wilding,7 John McCaffrey,8 Sergio V. Serrano,9 Vsevolod Matveev,10 Eleni Efstathiou,11 Stephane Oudard,12 Michael J. Morris,13Bruce Sizer,14 Peter J. Goebell,15 Johann S. de Bono,16 Prashni Paliwa,17 Susan Durham,17 Shinta Cheng,18 and Christopher Logothetis1 at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA
1MD Anderson Cancer Center, Houston, Texas, USA; 2Bristol-Myers Squibb, Montréal, Quebéc, Canada; 3Centre Hospitalier de l'Universite de Montreal, Montréal, Quebéc, Canada; 4Duke University, Durham, NC, USA; 5University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA; 6University Hospital del Mar-IMIM, Barcelona, Spain; 7University of Wisconsin Carbone Cancer Center, Madison, WI, USA; 8Irish Clinical Oncology Research Group (ICORG), Dublin, Ireland; 9Hospital Do Cancer de Barretos, Sao Paulo, Brazil; 10Russian Cancer Center, N.A. Blokhin, Moscow, Russian Federation; 11University of Athens, Athens, Greece; 12Hospital European Georges Pompidou, Paris, France; 13Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 14Essex County Hospital, Essex, UK; 15Friedrich-Alexander University, AURONTE, Erlangen, Germany; 16Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK; 17Bristol-Myers Squibb, Wallingford, CT, USA; 18Bristol-Myers Squibb, Lawrenceville, NJ, USA
View Full 2013 GU Cancers Symposium Coverage